AIM ImmunoTech Inc. (HEB) [Rocket]

In millions, except per share items	Dec-31-22	Dec-31-21	Dec-31-20	Dec-31-19	Dec-31-18	Dec-31-17	Dec-31-16	Dec-31-15
	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K
Cash flows from operating activities:
Net loss	-19.4	-19.1	-14.4	-9.4	-9.8	-8.3	-7.5	-15.2
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation of property and equipment	0.0	0.7	0.7	0.7	0.9	0.9	1.1	0.9
Redeemable warrants valuation adjustment					-1.2	-2.4	-1.7
Amortization of patent, trademark rights	0.2	0.1	0.1	0.1	0.0
Changes in ROU assets	-0.7	0.0	0.0	0.0
Equity-based compensation	1.0	1.6	1.0	0.9	0.9	0.6	0.4	0.2
Change in assets and liabilities:
Funds Receivable from New Jersey net operating loss	0.0	-0.6	-0.3
Prepaid expenses and other current assets and other non-current assets	-0.2	1.6	0.7	0.0	-0.3	0.0	0.0	0.1
Lease liability	0.7	0.0	0.0	0.0
Other Assets	-0.1
Accounts payable	0.2	-0.2	-0.1	-0.2	0.2	0.6	-0.3	-0.2
Accrued expenses	0.4	0.0	0.0	-0.7	-0.9	0.6	0.3	-1.1
Net cash used in operating activities	-16.1	-14.0	-10.4	-9.1	-10.6	-7.9	-7.4	-16.1

Cash flows from investing activities:
Proceeds from sale of marketable securities	10.1	22.3	10.0			2.8	3.4	6.8
Purchase of marketable securities	-2.7	-22.5	-18.6	-5.8
Proceeds from sale of property and equipment	3.9	0.2
Net cash (used in) provided by investing activities	11.0	-0.6	-9.2	-6.1	0.1	2.7	2.9	6.4

Cash flows from financing activities:
Proceeds from sale of stock, net of issuance costs	0.1	13.0	61.2	15.3	5.1	2.4	4.7	9.7
Net cash provided by financing activities	0.1	8.2	56.6	16.4	9.4	4.2	4.8	9.7

Supplemental disclosures of non-cash investing and financing cash flow information:
Unrealized gain (loss) on marketable securities
Conversion of Series B preferred